Most Read Articles
Naomi Adam, 2 years ago
Colorectal cancer is one of the leading cancers worldwide and one of the most difficult to treat because patients often present in later, metastatic stages of disease. Preventing blood vessel growth is a popular therapeutic strategy to help reduce the proliferation of cancerous tissue. Aflibercept (Zaltrap®, Sanofi) is a monoclonal antibody treatment that targets the cell signalling pathways of angiogenesis to prevent blood vessel growth in malignancies.
one year ago
A phase III, randomized, multi-center trial showed that dexamethasone helped reduce the incidence of radiation-induced pain flare in the treatment of bone metastases.
one year ago
Patients with advanced, epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) obtain survival benefit from EGFR tyrosine kinase inhibitor (TKI) treatment, a meta-analysis has shown.
Radha Chitale, one year ago
Genetically engineered T cells that target and destroy plasma cells may have the potential to cure patients with advanced multiple myeloma (MM), according to the results of a small, phase I/II trial in which one patient with over 90 percent of bone marrow cells affected was cleared of myeloma 1 month after treatment and researchers say he remains in stringent complete remission. [ASH 2015, abstract LBA 1]

Psoriasis may elevate risk of melanoma, haematologic cancers

2 months ago

There appears to be an increased risk of melanoma and haematologic cancers in patients with psoriasis compared with the general population, according to a recent study. This risk is not increased by systemic or biologic psoriasis treatments.

To examine the risk of melanoma and haematologic cancers in patients with psoriasis, as well as the association with various therapies, researchers used case-control and retrospective cohort designs. Fisher exact test was used to assess the risk with different types of therapies.

Patients with psoriasis were found to have 1.53 times higher risk of developing malignancy compared with patients without psoriasis (p<0.01). No significant differences were found in malignancy risk among those treated with topicals, phototherapy, systemics or biologic agents.

Furthermore, patients with psoriasis and malignancy did not have significantly worse survival that those without psoriasis, said researchers.

“It is possible that patients developed malignancy subsequent to the follow-up time included in the study,” they added.

A 2009 study found that many of the treatments for moderate to severe psoriasis, such as psoralen and ultraviolet A, traditional systemic therapies, and some biologic therapies, could elevate the risk of malignancy. It added that appropriate patient counselling and selection, as well as clinical follow-up, are warranted to maximize safety with such agents. [J Am Acad Dermatol 2009;60:1001-17]

On the other hand, a study by Christophers and colleagues concluded that more patients given biologic therapies improved from severe to moderate or mild psoriasis than those on other treatments. They added that more patients with plaque psoriasis and their dermatologists were satisfied with biologics than any other treatment. [J Dermatolog Treat 2013;24:193-8]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Adam, 2 years ago
Colorectal cancer is one of the leading cancers worldwide and one of the most difficult to treat because patients often present in later, metastatic stages of disease. Preventing blood vessel growth is a popular therapeutic strategy to help reduce the proliferation of cancerous tissue. Aflibercept (Zaltrap®, Sanofi) is a monoclonal antibody treatment that targets the cell signalling pathways of angiogenesis to prevent blood vessel growth in malignancies.
one year ago
A phase III, randomized, multi-center trial showed that dexamethasone helped reduce the incidence of radiation-induced pain flare in the treatment of bone metastases.
one year ago
Patients with advanced, epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) obtain survival benefit from EGFR tyrosine kinase inhibitor (TKI) treatment, a meta-analysis has shown.
Radha Chitale, one year ago
Genetically engineered T cells that target and destroy plasma cells may have the potential to cure patients with advanced multiple myeloma (MM), according to the results of a small, phase I/II trial in which one patient with over 90 percent of bone marrow cells affected was cleared of myeloma 1 month after treatment and researchers say he remains in stringent complete remission. [ASH 2015, abstract LBA 1]